Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)

DH Barouch; J Liu; L Peter; P Abbink; MJ Iampietro; A Cheung; G Alter; A Chung; AS Dugast; N Frahm; MJ McElrath; H Wenschuh; U Reimer; MS Seaman; MG Pau; M Weijtens; J Goudsmit; SR Walsh; R Dolin; LR Baden

Journal article

Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)

DH Barouch, J Liu, L Peter, P Abbink, MJ Iampietro, A Cheung, G Alter, A Chung, AS Dugast, N Frahm, MJ McElrath, H Wenschuh, U Reimer, MS Seaman, MG Pau, M Weijtens, J Goudsmit, SR Walsh, R Dolin, LR Baden

Journal of Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2013

DOI: 10.1093/infdis/jis671

Abstract

Background. Adenovirus serotype 26 (Ad26) has been developed as a novel candidate vaccine vector for human immunodeficiency virus type 1 (HIV-1) and other pathogens. The primary safety and immunogenicity data from the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) 001 trial, the first-in-human evaluation of a prototype Ad26 vector-based vaccine expressing clade A HIV-1 Env (Ad26.ENVA.01), are reported concurrently with this article. Here, we characterize in greater detail the humoral and cellular immune responses elicited by Ad26.ENVA.01 in humans.Methods. Samples from the IPCAVD 001 trial were used for humoral and cellular immunogenicity assays.Results. We observe..

View full abstract

University of Melbourne Researchers

Amy Chung Author

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

This work was supported by the National Institutes of Health (grants AI060354, AI066305, AI066924, AI069412, AI078526, and AI096040), the Bill & Melinda Gates Foundation, and the Ragon Institute of MGH, MIT, and Harvard.